H. Lundbeck A/S (CPSE: HLUN B)
Health Care · Pharmaceuticals · DK
Dkr62.15
+2.22% today · +42.8% 1Y
Public summary
A free snapshot of H. Lundbeck A/S, with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app H. Lundbeck A/S (CPSE: HLUN B) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.99B.
Over the last twelve months the share price has gained 42.8%, trading between 35.30 and 62.85.
Tweenvest scores H. Lundbeck A/S across four factors: quality 79/100, value 45/100, growth 78/100, dividend 82/100. Its strongest factor is dividend.
HLUN B price history
Key figures
- Market cap
- $8.99B
- Revenue (TTM)
- $3.99B
- P/E
- 14.92
- EPS
- 4.08
- Dividend yield
- 1.87%
- Beta (5Y)
- 0.19
- 52-week high
- Dkr62.85
- 52-week low
- Dkr35.30
- Avg volume (3M)
- —
- Shares outstanding
- 991.23M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sichuan Kelun Pharmaceutical Co., Ltd.SZSE: 002422 | $10.17B | CN¥42.67 | -1.77% |
| Haisco Pharmaceutical Group Co., Ltd.SZSE: 002653 | $9.64B | CN¥58.03 | -1.41% |
| Lupin LimitedBSE: 500257 | $9.56B | Rs1,953.90 | -0.94% |
| Eisai Co., Ltd.TSE: 4523 | $9.29B | ¥5,240.00 | -1.06% |
| Kyowa Kirin Co., Ltd.TSE: 4151 | $8.39B | ¥2,552.50 | -1.05% |
| Krka, d. d.LJSE: KRKG | $8.29B | €250.00 | -0.40% |
| ALK-Abelló A/SCPSE: ALK B | $8.14B | Dkr248.40 | -0.16% |
| Glenmark Pharmaceuticals LimitedNSEI: GLENMARK | $7.88B | Rs2,608.50 | -1.42% |